Stifel Nicolaus set a $95.00 price objective on Puma Biotechnology (NASDAQ:PBYI) in a research report sent to investors on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on the company. Credit Suisse Group set a $106.00 target price on Puma Biotechnology and gave the stock a buy rating in a research report on Friday, March 2nd. BidaskClub cut Puma Biotechnology from a buy rating to a hold rating in a research report on Saturday, March 3rd. Barclays decreased their target price on Puma Biotechnology from $92.00 to $90.00 and set an overweight rating for the company in a research report on Friday, March 2nd. Zacks Investment Research raised Puma Biotechnology from a sell rating to a hold rating in a research report on Friday, January 26th. Finally, Bank of America decreased their target price on Puma Biotechnology from $135.00 to $115.00 and set a buy rating for the company in a research report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $103.11.
Puma Biotechnology (NASDAQ:PBYI) opened at $79.45 on Friday. The stock has a market capitalization of $2,980.00, a price-to-earnings ratio of -10.11 and a beta of 0.26. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $136.90.
In related news, SVP Richard Paul Bryce sold 1,860 shares of Puma Biotechnology stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $172,515.00. Following the completion of the sale, the senior vice president now owns 25,379 shares of the company’s stock, valued at $2,353,902.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alan H. Auerbach sold 10,692 shares of Puma Biotechnology stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $92.75, for a total value of $991,683.00. Following the sale, the insider now directly owns 4,155,931 shares of the company’s stock, valued at approximately $385,462,600.25. The disclosure for this sale can be found here. 21.10% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBYI. First Republic Investment Management Inc. acquired a new stake in Puma Biotechnology during the fourth quarter valued at $208,000. Sei Investments Co. acquired a new stake in shares of Puma Biotechnology in the third quarter worth about $256,000. Jafra Capital Management LP acquired a new stake in shares of Puma Biotechnology in the fourth quarter worth about $257,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Puma Biotechnology in the fourth quarter worth about $288,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in shares of Puma Biotechnology in the fourth quarter worth about $292,000. 96.47% of the stock is owned by hedge funds and other institutional investors.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.